Jean-Paul Clozel downplays recruitment delays holding up PhIII for Fabry disease
Idorsia may have run into a bit of delay with the Phase III registrational trial for one of its lead programs, but CEO Jean-Paul Clozel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
